logo

For the Inventor, By the Inventor

Brussels, Belgium

Christophe Lurquin

USPTO Granted Patents = 18


Average Co-Inventor Count = 5.4

ph-index = 9

Forward Citations = 301(Granted Patents)


Company Filing History:

goldMedal16 out of 525 
 
Ludwig Institute for Cancer Research Limited
 patents
silverMedal2 out of 832,891 
Other
 patents

Years Active: 1994-2011

Loading Chart...
Loading Chart...
18 patents (USPTO):Explore Patents
1. 7923534 - Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3 (2011-04-12),
2. 7351409 - Tumor antigens and CTL clones isolated by a novel procedure (2008-04-01),
3. RE40089 - Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor (2008-02-18),
4. 6710172 - Tumor antigens and CTL clones isolated by a novel procedure (2004-03-23),
5. 6531451 - Tumor antigens and CTL clones isolated by a novel procedure (2003-03-11),
6. 6488932 - Method for treating cancer by administering MAGE-derived peptides (2002-12-03),
7. 6407063 - Tumor antigens and CTL clones isolated by a novel procedure (2002-06-18),
8. 6392016 - Isolated protein molecules which are members of the MAGE-B family (2002-05-21),
9. 6034214 - Isolated nonapeptides which bind to HLA molecules and provoke lysis by (2000-03-07),
10. 6017705 - Isolated nucleic acid molecules which are members of the MAGE-B family (2000-01-25),
11. 5925729 - Tumor rejection antigen precursors, tumor rejection antigens and uses (1999-07-20),
12. 5763165 - Method for determining lung adenocarcinomas by assaying for one or more (1998-06-09),
13. 5763155 - Method for determining lung adenocarcinomas by assaying for one or more (1998-06-09),
14. 5759783 - Method of screening for cancer by detecting messenger RNA for a MAGE-XP (1998-06-02),
15. 5587289 - Isolated nucleic acid molecules which are members of the MAGE-Xp family (1996-12-24),

Title: The Innovative Contributions of Christophe Lurquin

Introduction

Christophe Lurquin is a prominent inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly in the development of tumor antigens and their therapeutic applications. With a total of 18 patents to his name, Lurquin's work has had a profound impact on the understanding and treatment of cancer.

Latest Patents

Among his latest patents, Lurquin has developed isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3. This invention relates to an isolated DNA sequence that codes for an antigen expressed by tumor cells, which is recognized by cytotoxic T cells, leading to the lysis of the tumor that expresses it. Additionally, he has described cells transfected by this DNA sequence, along with various therapeutic and diagnostic uses arising from the properties of the DNA and the antigen it codes for. Another notable patent involves the isolation of cytotoxic T lymphocyte (CTL) clones that are specific for proteins of the MAGE family. This invention details a novel procedure for isolating CTL clones through successive stimulation and testing of lymphocytes with antigen-presenting cells that present antigens derived from different expression systems.

Career Highlights

Lurquin has worked with the Ludwig Institute for Cancer Research Limited, where he has furthered his research in cancer immunology. His innovative approaches have led to advancements in the understanding of tumor antigens and their role in immune response.

Collaborations

Throughout his career, Christophe Lurquin has collaborated with notable scientists such as Pierre Van Der Bruggen and Thierry R Boon-Falleur. These collaborations have enriched his research and contributed to the development of groundbreaking technologies in cancer treatment.

Conclusion

Christophe Lurquin's contributions to cancer research through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for innovative therapeutic strategies against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…